General Information of the Molecule (ID: Mol04438)
Name
E3 ubiquitin-protein ligase RNF38 (RNF38) ,Homo sapiens
Synonyms
RING finger protein 38; RING-type E3 ubiquitin transferase RNF38
    Click to Show/Hide
Molecule Type
Protein
Gene Name
RNF38
Gene ID
152006
Sequence
MACKISPGANSASLPGHPNKVICERVRLQSLFPLLPSDQNTTVQEDAHFKAFFQSEDSPS
PKRQRLSHSVFDYTSASPAPSPPMRPWEMTSNRQPPSVRPSQHHFSGERCNTPARNRRS
P PVRRQRGRRDRLSRHNSISQDENYHHLPYAQQQAIEEPRAFHPPNVSPRLLHPAAHPP
QQ NAVMVDIHDQLHQGTVPVSYTVTTVAPHGIPLCTGQHIPACSTQQVPGCSVVFSGQH
LPV CSVPPPMLQACSVQHLPVPYAAFPPLISSDPFLIHPPHLSPHHPPHLPPPGQFVPF
QTQQ SRSPLQRIENEVELLGEHLPVGGFTYPPSAHPPTLPPSAPLQFLTHDPLHQEVSF
GVPYP PFMPRRLTGRSRYRSQQPIPPPPYHPSLLPYVLSMLPVPPAVGPTFSFELDVED
GEVENY EALLNLAERLGEAKPRGLTKADIEQLPSYRFNPNNHQSEQTLCVVCMCDFESR
QLLRVLP CNHEFHAKCVDKWLKANRTCPICRADASEVHRDSE
    Click to Show/Hide
Function
Acts as an E3 ubiquitin-protein ligase able to ubiquitinatep53/TP53 which promotes its relocalization to discrete foci associatedwith PML nuclear bodies. Exhibits preference for UBE2D2 as a E2 enzyme.{ECO:0000269|PubMed:23973461}.
    Click to Show/Hide
Uniprot ID
RNF38_HUMAN
Ensembl ID
ENSG0000013707518
HGNC ID
HGNC:18052
        Click to Show/Hide the Complete Species Lineage
Kingdom: Metazoa
Phylum: Chordata
Class: Mammalia
Order: Primates
Family: Hominidae
Genus: Homo
Species: Homo sapiens
Type(s) of Resistant Mechanism of This Molecule
  UAPP: Unusual Activation of Pro-survival Pathway
Drug Resistance Data Categorized by Drug
Approved Drug(s)
1 drug(s) in total
Click to Show/Hide the Full List of Drugs
Gilteritinib
Click to Show/Hide
Drug Sensitivity Data Categorized by Their Corresponding Mechanisms
  Unusual Activation of Pro-survival Pathway (UAPP) Click to Show/Hide
Disease Class: Acute myeloid leukemia [ICD-11: 2A60.0] [1]
Sensitive Disease Acute myeloid leukemia [ICD-11: 2A60.0]
Sensitive Drug Gilteritinib
Molecule Alteration Expression
Up-regulation
Experimental Note Revealed Based on the Cell Line Data
Cell Pathway Regulation Cell autophagy Inhibition hsa04140
In Vitro Model MV4-11/Gilteritinib si-RNF38 cells myeloid Homo sapiens (Human) N.A.
Experiment for
Molecule Alteration
Western blot assay; qRT-PCR
Experiment for
Drug Resistance
CCK8 assay
Mechanism Description In gilteritinib-resistant AML cells, autophagy-related markers, mRFP-GFP-LC3 signals and autophagosome numbers were significantly enhanced. Autophagy inhibitor 3-MA could suppress gilteritinib resistance in AML cells. RNF38 knockdown inhibited gilteritinib resistance and autophagy in AML cells. Mechanistically, RNF38 reduced LMX1A expression by inducing its ubiquitination. RNF38 overexpression reversed the inhibitory effect of LMX1A on gilteritinib resistance and autophagy in AML cells, as well as AML tumor growth in vivo, while these effects could be abolished by proteasome inhibitor MG136.
Disease Class: Acute myeloid leukemia [ICD-11: 2A60.0] [1]
Sensitive Disease Acute myeloid leukemia [ICD-11: 2A60.0]
Sensitive Drug Gilteritinib
Molecule Alteration Expression
Up-regulation
Experimental Note Revealed Based on the Cell Line Data
Cell Pathway Regulation Cell autophagy Inhibition hsa04140
In Vitro Model MOLM-13/Gilteritinib si-RNF38 cells myeloid Homo sapiens (Human) N.A.
Experiment for
Molecule Alteration
Western blot assay; qRT-PCR
Experiment for
Drug Resistance
CCK8 assay
Mechanism Description In gilteritinib-resistant AML cells, autophagy-related markers, mRFP-GFP-LC3 signals and autophagosome numbers were significantly enhanced. Autophagy inhibitor 3-MA could suppress gilteritinib resistance in AML cells. RNF38 knockdown inhibited gilteritinib resistance and autophagy in AML cells. Mechanistically, RNF38 reduced LMX1A expression by inducing its ubiquitination. RNF38 overexpression reversed the inhibitory effect of LMX1A on gilteritinib resistance and autophagy in AML cells, as well as AML tumor growth in vivo, while these effects could be abolished by proteasome inhibitor MG137.
References
Ref 1 RNF38 promotes gilteritinib resistance in acute myeloid leukemia via inducing autophagy by regulating ubiquitination of LMX1A. Cell Biol Toxicol. 2024 Nov 28;40(1):105.

If you find any error in data or bug in web service, please kindly report it to Dr. Sun and Dr. Yu.